Hansa Biopharma On Clearing The Path To Kidney Transplant

Renée Aguiar-Lucander, CEO of Hansa Biopharma, discussed the company’s leading asset, its journey toward US FDA approval and the trials and tribulations of completing a Phase III program.

Episode metadata supplied by the publisher feed · Published Feb 16, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Hansa Biopharma On Clearing The Path To Kidney Transplant

0:00 37:45

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Citeline Podcasts?

This episode is 37 minutes long.

When was this Citeline Podcasts episode published?

This episode was published on February 16, 2026.

Can I download this Citeline Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!